centerforbiosimilars16 小时
Eye on Pharma: Teva, Formycon, Celltrion Biosimilar Updates in Global Markets
Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...
centerforbiosimilars1 天
Dan Danielson, RPh, MS
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf ...
centerforbiosimilars1 天
Prateek Yadav, MPTh, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars1 天
Chase Ibia, PharmD Candidate
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars1 天
No Disease Activity Changes After Children With IBD Switched to Infliximab Biosimilar
A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant ...
centerforbiosimilars2 天
Courtney Flaherty
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2 天
Dracey Poore
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2 天
The Top 5 Biosimilar Articles for the Week of January 20
Number 2: Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar competition, according to Samsung Bioepis’ most recent market report, ...
centerforbiosimilars3 天
Robert Spina, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars4 天
Christina Corridon, MPH, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars4 天
Mayuri Mathuria, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...